TOP > 外国特許検索 > METHOD FOR INDUCING MACROPHAGES, INDUCER FOR ANTI-INFLAMMATORY MACROPHAGES AND PHARMACEUTICAL COMPOSITION

METHOD FOR INDUCING MACROPHAGES, INDUCER FOR ANTI-INFLAMMATORY MACROPHAGES AND PHARMACEUTICAL COMPOSITION NEW

外国特許コード F200010242
整理番号 (S2019-0118-N0)
掲載日 2020年10月30日
出願国 世界知的所有権機関(WIPO)
国際出願番号 2020JP009639
国際公開番号 WO2020184425
国際出願日 令和2年3月6日(2020.3.6)
国際公開日 令和2年9月17日(2020.9.17)
優先権データ
  • 特願2019-042795 (2019.3.8) JP
発明の名称 (英語) METHOD FOR INDUCING MACROPHAGES, INDUCER FOR ANTI-INFLAMMATORY MACROPHAGES AND PHARMACEUTICAL COMPOSITION NEW
発明の概要(英語) This method for inducing macrophages involves culturing macrophages in the presence of exosomes produced from interferon γ-added mesenchymal stem cells, and inducing anti-inflammatory macrophages. This inducer for anti-inflammatory macrophages contains exosomes produced from interferon γ-added mesenchymal stem cells as an effective ingredient. This pharmaceutical composition comprises said inducer.
従来技術、競合技術の概要(英語) BACKGROUND ART
Mesenchymal stem cells (MSC) can be collected not only from bone marrow but also from medical wastes such as adipose tissue and umbilical cord tissue, have low antigenic properties, can also use other cells, and have various roles such as anti-inflammatory, antifibrosis, angiogenesis, antioxidation, and the like. However, it has been reported that MSC is slightly different depending on the cell type from which MSC is derived, and the properties of MSC are changed when they enter into culture conditions and living bodies, and the mechanism of the effect has not been clarified yet. MSC is expected to act on many immune cells through the production of cytokines, chemokines, growth factors, exosomes, and the like as "conducting cells", but the influence on macrophages is paid attention to the pathology of liver cirrhosis.
So far, the inventors have found that MSC changes the polarity of myeloid-derived cultured macrophages to), also referred to as anti-inflammatory macrophages ("M2 macrophages", thereby acting on fibrogenesis improvement and regeneration promotion during liver cirrhosis, for example, see) Non-Patent Document 1.
However, it is known that most of MSC are delivered to the lungs when administered intravenously and very few of MSC are delivered to the liver. Nevertheless, it is presumed that some MSC expression substance is involved in liver cirrhosis because of showing the above effect on liver cirrhosis, but the detailed mechanism of which substance changes the polarity of macrophages has not been clarified.
  • 出願人(英語)
  • ※2012年7月以前掲載分については米国以外のすべての指定国
  • NIIGATA UNIVERSITY
  • 発明者(英語)
  • TERAI Syuji
  • TSUCHIYA Atsunori
  • TAKEUCHI Suguru
国際特許分類(IPC)
指定国 National States: AE AG AL AM AO AT AU AZ BA BB BG BH BN BR BW BY BZ CA CH CL CN CO CR CU CZ DE DJ DK DM DO DZ EC EE EG ES FI GB GD GE GH GM GT HN HR HU ID IL IN IR IS JO JP KE KG KH KN KP KR KW KZ LA LC LK LR LS LU LY MA MD ME MG MK MN MW MX MY MZ NA NG NI NO NZ OM PA PE PG PH PL PT QA RO RS RU RW SA SC SD SE SG SK SL ST SV SY TH TJ TM TN TR TT TZ UA UG US UZ VC VN WS ZA ZM ZW
ARIPO: BW GH GM KE LR LS MW MZ NA RW SD SL SZ TZ UG ZM ZW
EAPO: AM AZ BY KG KZ RU TJ TM
EPO: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
OAPI: BF BJ CF CG CI CM GA GN GQ GW KM ML MR NE SN ST TD TG
ライセンスをご希望の方、特許の内容に興味を持たれた方は、下記「問合せ先」までお問い合わせください。

PAGE TOP

close
close
close
close
close
close